- Home
- THAR vs TOVX Comparison
THAR vs TOVX Comparison
Compare THAR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- TOVX
- Stock Information
- Founded
- THAR 2017
- TOVX 2001
- Country
- THAR United States
- TOVX United States
- Employees
- THAR N/A
- TOVX N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- TOVX Health Care
- Exchange
- THAR Nasdaq
- TOVX Nasdaq
- Market Cap
- THAR 2.8M
- TOVX 3.1M
- IPO Year
- THAR 2022
- TOVX 2006
- Fundamental
- Price
- THAR $2.17
- TOVX $1.37
- Analyst Decision
- THAR
- TOVX Strong Buy
- Analyst Count
- THAR 0
- TOVX 1
- Target Price
- THAR N/A
- TOVX $6.00
- AVG Volume (30 Days)
- THAR 3.3M
- TOVX 4.8M
- Earning Date
- THAR 11-07-2024
- TOVX 11-12-2024
- Dividend Yield
- THAR N/A
- TOVX N/A
- EPS Growth
- THAR N/A
- TOVX N/A
- EPS
- THAR N/A
- TOVX N/A
- Revenue
- THAR N/A
- TOVX N/A
- Revenue This Year
- THAR N/A
- TOVX N/A
- Revenue Next Year
- THAR N/A
- TOVX N/A
- P/E Ratio
- THAR N/A
- TOVX N/A
- Revenue Growth
- THAR N/A
- TOVX N/A
- 52 Week Low
- THAR $1.84
- TOVX $1.24
- 52 Week High
- THAR $79.50
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- THAR 44.85
- TOVX 37.71
- Support Level
- THAR $1.90
- TOVX $1.31
- Resistance Level
- THAR $2.33
- TOVX $2.22
- Average True Range (ATR)
- THAR 0.54
- TOVX 0.24
- MACD
- THAR -0.04
- TOVX -0.00
- Stochastic Oscillator
- THAR 6.22
- TOVX 4.51
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.